Transcript Treatment of Erectile Dysfunction

ERECTILE DYSFUNCTION
Overview
Erectile dysfunction (ED) is defined as the inability to attain
and maintain an erection sufficient to permit satisfactory
sexual intercourse.
Medical and Surgical Therapy of Erectile Dysfunction. Shindel A, Brant WO, Bochinski D, Bella AJ, Lue TF.
In: De Groot LJ, Beck-Peccoz P, Chrousos G, Dungan K, Grossman A, Hershman JM, Koch C, McLachlan R, New M,
Rebar R, Singer F, Vinik A, Weickert MO, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.;
2000-2014 Accessed May 24 2015 http://www.ncbi.nlm.nih.gov/books/NBK278925/#med-surg-thrpy-ed.toc-8-1physiology-of-erections
Overview
40% of men over the age of 40 ("40 over 40" rule) have ED.
As a man gets older, ED is more common than having
normal erectile function. In fact, after age 50-60, more
men have ED than optimal (normal) erections.
Medical and Surgical Therapy of Erectile Dysfunction. Shindel A, Brant WO, Bochinski D, Bella AJ, Lue TF.
In: De Groot LJ, Beck-Peccoz P, Chrousos G, Dungan K, Grossman A, Hershman JM, Koch C, McLachlan R, New M,
Rebar R, Singer F, Vinik A, Weickert MO, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.;
2000-2014 Accessed May 24 2015 http://www.ncbi.nlm.nih.gov/books/NBK278925/#med-surg-thrpy-ed.toc-8-1physiology-of-erections
MASSACHUSETTS MALE AGING STUDY:
KEY PREVALENCE STUDY OF ED
Men aged 40 to 70 years (N=1290)
Minimal ED
17%
No ED
48%
ED
52%
Moderate ED
25%
Complete ED
10%
Minimal ED, “usually able to get or keep an erection.”
Moderate ED, “sometimes able to get and maintain an erection.”
Complete ED, “unable to get and keep an erection.”
Source Material Feldman HA et al. J Urol. 1994;151:54-61.
Overview
30 million men in the United States are estimated to have
varying degrees of ED, with similar numbers in the EU.
Fewer men in the EU obtain treatment compared to the
Americas; cost of medications is the main barrier to care.
Medical and Surgical Therapy of Erectile Dysfunction. Shindel A, Brant WO, Bochinski D, Bella AJ, Lue TF.
In: De Groot LJ, Beck-Peccoz P, Chrousos G, Dungan K, Grossman A, Hershman JM, Koch C, McLachlan R, New M,
Rebar R, Singer F, Vinik A, Weickert MO, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.;
2000-2014 Accessed May 24 2015 http://www.ncbi.nlm.nih.gov/books/NBK278925/#med-surg-thrpy-ed.toc-8-1physiology-of-erections
Overview
30 million men in the United States are estimated to have
varying degrees of ED, with similar numbers in the EU.
Fewer men in the EU obtain treatment compared to the
Americas; cost is the main barrier to care.
Figure from 2014-2018 Global Erectile Dysfunction Drugs Market.
Research by Technavio Insights. Purchased by Biopharmcor.
Causes of Erectile Dysfunction
Some common causes of ED are diabetes, cardiovascular
disease, hypertension, abnormal cholesterol, smoking,
obesity, lack of physical fitness and exercise, psychological
issues, overuse of alcohol and the use of medications for
other diseases (side-effect of medications such as blood
pressure pills and anti-depressants).
2015 CUA Practice guidelines for erectile dysfunction. Bella AJ, Lee JC, Carrier S, Bénard F, Brock GB. Can
Urol Assoc J. 2015 Jan-Feb;9(1-2):23-9. Access May 24 2015 at http://www.cua.org/en/guidelines
Impact of Erectile Dysfunction
ED is a highly prevalent condition, which affects the
physical and psychosocial (psychological) well-being
and quality of life for thousands of men, their partners,
and families around the world.
ED leads to stress, anxiety and self-confidence issues, in
addition to the physical inability to perform sexually.
It is not surprising that the global market for ED
medications was over $4.1 billion USD in 2013.
2015 CUA Practice guidelines for erectile dysfunction. Bella AJ, Lee JC, Carrier S, Bénard F, Brock GB. Can
Urol Assoc J. 2015 Jan-Feb;9(1-2):23-9. Access May 24 2015 at http://www.cua.org/en/guidelines
*Data from 2014-2018 Global Erectile Dysfunction Drugs Market. Research by Technavio Insights.
Purchased by Biopharmcor.
Treatment of Erectile Dysfunction
The treatment of ED in general was revolutionized by the
introduction of the PDE5 inhibitor (PDE5I) class of
medications. The first of these was sildenafil (Viagra®),
followed by vardenafil (Levitra®/Staxyn®) and tadalafil
(Cialis®). In April 2012 a fourth PDE5I, avanafil (Stendra®)*,
received FDA approval.
ED treatment is successful using pills (oral therapy) for the
majority of men regardless of the underlying cause of ED.
2015 CUA Practice guidelines for erectile dysfunction. Bella AJ, Lee JC, Carrier S, Bénard F, Brock GB. Can
Urol Assoc J. 2015 Jan-Feb;9(1-2):23-9. Access May 24 2015 at http://www.cua.org/en/guidelines
*Data from 2014-2018 Global Erectile Dysfunction Drugs Market. Research by Technavio Insights.
Purchased by Biopharmcor.
Treatment of Erectile Dysfunction
2015 CUA Practice guidelines for erectile dysfunction. Bella AJ, Lee JC, Carrier S, Bénard F, Brock GB. Can
Urol Assoc J. 2015 Jan-Feb;9(1-2):23-9. Access May 24 2015 at http://www.cua.org/en/guidelines
Full figure and article available for public review.
Treatment of Erectile Dysfunction
The majority of men will have an excellent treatment
response to PDE5Is. They will not require more invasive
treatments.
Second-line treatments for ED include intracavernous
injections (needle delivery of medication into the penis),
vacuum erection device, or intraurethral alprostadil (a small
pellet inserted into the opening of the urinary passage).
Third-line treatment includes surgical insertion of an
internal penile prosthesis (pump).
2015 CUA Practice guidelines for erectile dysfunction. Bella AJ, Lee JC, Carrier S, Bénard F, Brock GB. Can
Urol Assoc J. 2015 Jan-Feb;9(1-2):23-9. Access May 24 2015 at http://www.cua.org/en/guidelines
Summary
Erectile dysfunction is common, occurs in more than
half of men after age 50, and significantly impacts
quality of life.
Safe, effective oral drugs are available. The cost of these
medications is the primary barrier for patient care.
Opportunities exist for Biopharmcor to develop new
generic medications to successfully treat men with ED.
Key Aspects of Erectile Dysfunction
Point 1: ED rates are increasing globally.
Point 2: Safe and effective oral treatments are available.
Point 3: First-line treatment for EAU, AUA and CUA
guidelines are PDE5Is (pills).
Point 4: Cost is the main barrier to successful ED
treatment. Development of generic medications offers a
safe and effective option.
EAU – European Association of Urology
AUA – American Urological Association
CUA – Canadian Urological Association
Further Information
1.Please refer to the FAQ sections for Men’s Health and Erectile Dysfunction on the
Biopharmcor website.
2. European Association of Urology at http://patients.uroweb.org
3. American Urological Association patient care website at
http://www.urologyhealth.org/
4. 2015 Canadian Urological Association Guidelines for the Treatment of Erectile
Dysfunction at:
http://www.cua.org/themes/web/assets/files/guidelines/en/erectile_dysfunction_fe
b_2015.pdf.